TUSTIN, Calif. (Map) -
The posted conference call script outlines prepared remarks AMDL's executive management made covering the Company's financial results for the first quarter of FY2008 and the subsequent question and answers from shareholders.
Highlighted comments from AMDL's CEO Gary Dreher included: -- We have responded to the U.S. FDA regarding requests for information on our DR-70(TM) cancer test within the time period required; -- AMDL's executive management team is committed to increasing shareholder communications, including formally issuing corporate guidance; -- We are focused on growing annual sales at a minimum rate of 100 percent over the next three years. -- 2007 sales were $15 million and we are on track to at least doubling sales in 2008; -- AMDL will leverage its land holdings in China (estimated to be worth between $15-$21 million) to gain a new credit facility in place by Q3, 2008. -- We plan to finance continued growth with debt and credit lines. We do not plan to pursue the same type of 25 percent discounted equity funding as we've done in previous rounds; -- AMDL's anti-aging Goodnak product line is enjoying high growth demand and we anticipate it will be exported to the US and Europe in the future; -- AMDL's head of R&D Dr. Andrea Small-Howard has concluded that the HPV Test Kit licensed by the Company for distribution in China, Hong Kong, Taiwan, Singapore, Malaysia, Thailand, Cambodia and Vietnam has numerous advantages over other test kits for HPV and can become a major product for the Company.
About AMDL:
AMDL, Inc. is a global specialty pharmaceutical company. The company is
headquartered in
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer market
in the world:
IR Contact: Mr.
Direct: 949.707.5365 Voicemail: 714.505.4460
|
Advertisement
|


